Literature DB >> 2310657

Development of tolerance to nifedipine in patients with stable angina pectoris.

S Y Martsevich1, V I Metelitsa, D O Rumiantsev, V K Piotrovskii, I D Slastnikova, L V Egorov, V A Vygodin.   

Abstract

1. The possibility of development of tolerance to the anti-ischaemic and anti-anginal effects of nifedipine during sustained administration for 2 months was studied in 15 patients with stable angina pectoris by means of repeated exercise tests on a treadmill. 2. After acute administration of nifedipine (20-30 mg) substantial anti-ischaemic and anti-anginal effects lasted for at least 4 h in all patients. 3. During sustained nifedipine treatment with a dose schedule which provided continuous anti-ischaemic effect during a day (mean daily dose 82.7 +/- 6.0 mg, range 60-120 mg) a substantial attenuation of this effect was registered. The duration of the anti-ischaemic effect was 5.4 +/- 0.3 h after acute administration, decreasing significantly to 3.6 +/- 0.4 h during sustained administration. 4. The attenuation of the nifedipine effect was not associated with worsening of the patients' condition. 5. Plasma concentrations of nifedipine and its metabolite were similar after acute administration and during sustained treatment. Protein binding of nifedipine also remained constant during the study. 6. There was marked interindividual variation in the degree of attenuation of the nifedipine effect during sustained administration. In five patients nearly complete loss of nifedipine efficacy was registered. Eight to ten days after stopping regular administration of nifedipine only partial restoration of nifedipine effect was observed. 7. We conclude that during sustained nifedipine administration tolerance to its anti-ischaemic, anti-anginal and circulatory effects develops in a substantial number of patients with stable angina pectoris.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2310657      PMCID: PMC1380135          DOI: 10.1111/j.1365-2125.1990.tb03645.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  12 in total

1.  Comparison of nitroglycerin patches and nifedipine.

Authors:  J E Eldridge; D C Burdick; R H Jones; K F Hossack
Journal:  J Cardiovasc Pharmacol       Date:  1987-09       Impact factor: 3.105

2.  Tolerance to isosorbide dinitrate: rate of development and reversal.

Authors:  J O Parker; H L Fung; D Ruggirello; J A Stone
Journal:  Circulation       Date:  1983-11       Impact factor: 29.690

3.  Efficacy of nifedipine therapy in patients with refractory angina pectoris: significance of the presence of coronary vasospasm.

Authors:  P H Stone; J E Muller; Z G Turi; E Geltman; A S Jaffe; E Braunwald
Journal:  Am Heart J       Date:  1983-10       Impact factor: 4.749

4.  [Method of studying the pharmacodynamics of anti-angina drugs by means of repeated exercise tests].

Authors:  V A Nazarenko; S A Nikolenko
Journal:  Kardiologiia       Date:  1981-01       Impact factor: 0.395

5.  Production of ischaemic cardiac pain by nifedipine.

Authors:  A G Jariwalla; E G Anderson
Journal:  Br Med J       Date:  1978-05-06

6.  New transdermal and transmucosal nitroglycerin delivery systems in patients with ischaemic heart disease.

Authors:  V I Metelitsa; V K Piotrovskii; O S Ryabokon; S V Blagodatskikh
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

7.  Diltiazem dose responses in sustained therapy for stable angina pectoris.

Authors:  J L McCans
Journal:  Can J Cardiol       Date:  1986 Nov-Dec       Impact factor: 5.223

8.  Interim report of multicenter double-blind, placebo-controlled studies of nifedipine in chronic stable angina.

Authors:  H S Mueller; R A Chahine
Journal:  Am J Med       Date:  1981-10       Impact factor: 4.965

9.  Nifedipine gastrointestinal therapeutic system in stable angina pectoris. Results of a multicenter open-label crossover comparison with standard nifedipine.

Authors:  G W Vetrovec; V E Parker; S Cole; P M Procacci; B Tabatznik; R Terry
Journal:  Am J Med       Date:  1987-12-21       Impact factor: 4.965

10.  Pharmacokinetics and hemodynamic effects of long-term nifedipine treatment in hypertensive patients.

Authors:  C H Kleinbloesem; P van Brummelen; H Faber; D D Breimer
Journal:  J Cardiovasc Pharmacol       Date:  1987-02       Impact factor: 3.105

View more
  4 in total

Review 1.  Sustained release nifedipine formulations. An appraisal of their current uses and prospective roles in the treatment of hypertension, ischaemic heart disease and peripheral vascular disorders.

Authors:  D Murdoch; R N Brogden
Journal:  Drugs       Date:  1991-05       Impact factor: 9.546

2.  Evaluation of the antianginal effect of nifedipine: influence of formulation dependent pharmacokinetics.

Authors:  B W Karlson; H Emanuelsson; J Herlitz; J E Nilsson; G Olsson
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 3.  The nifedipine gastrointestinal therapeutic system (GITS). Evaluation of pharmaceutical, pharmacokinetic and pharmacological properties.

Authors:  J S Grundy; R T Foster
Journal:  Clin Pharmacokinet       Date:  1996-01       Impact factor: 6.447

4.  Serum concentration-effect relationship of (+/-)-nicardipine and nifedipine in elderly hypertensive patients.

Authors:  H C Porchet; F Loew; L Gauthey; P Dayer
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.